Submit your email to push it up the queue
Wyeth LLC, a prominent player in the pharmaceutical and biotechnology industry, is headquartered in the United States. Founded in the early 20th century, the company has established itself as a leader in developing innovative healthcare solutions, particularly in areas such as vaccines, biologics, and specialty pharmaceuticals. With a strong operational presence across North America and Europe, Wyeth is renowned for its commitment to research and development, resulting in a portfolio of unique products that address critical health challenges. The company has achieved significant milestones, including groundbreaking advancements in immunology and oncology, solidifying its market position as a trusted provider of high-quality medical solutions. Wyeth's dedication to improving patient outcomes and its focus on scientific excellence continue to drive its success in the competitive healthcare landscape.
How does Wyeth LLC's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Wyeth LLC's score of 82 is higher than 90% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Wyeth LLC, headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. However, as a current subsidiary of Pfizer Inc., Wyeth's climate commitments and initiatives are influenced by its parent company's sustainability strategies. Pfizer Inc. has established science-based targets (SBTi) aimed at reducing greenhouse gas emissions across its operations. These targets are cascaded down to Wyeth LLC, reflecting a commitment to addressing climate change through measurable actions. While specific reduction targets for Wyeth are not detailed, Pfizer's overarching initiatives include commitments to reduce Scope 1, 2, and 3 emissions, which encompass direct emissions from owned or controlled sources, indirect emissions from the generation of purchased energy, and other indirect emissions in the value chain. Wyeth LLC's climate strategy aligns with Pfizer's broader sustainability goals, which include participation in initiatives such as the Carbon Disclosure Project (CDP) and RE100, aimed at transitioning to 100% renewable energy. The absence of specific emissions data does not diminish Wyeth's commitment to environmental responsibility, as it operates under the guidance of Pfizer's established climate framework.
Access structured emissions data, company-specific emission factors, and source documents
2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | - | - | - | - | - | - | - | - | 000,000,000 | 000,000,000 | - | - | - |
Scope 2 | - | - | - | - | - | - | - | - | 000,000,000 | 000,000,000 | - | - | - |
Scope 3 | - | - | - | - | - | - | - | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Wyeth LLC is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.